After her double preventive mastectomy, Angelina Jolie underwent a preventive ablation of the ovaries. Indeed, due to a genetic defect, her risk of developing ovarian cancer was also high. Now, a new generation genetic test facilitates the simultaneous estimation of the risk for several cancers.
"About 65% of breast cancer patients develop mild to severe anemia due to illness or chemotherapy," says Dr. Veronika Pasquinelli, a hospital specialist at the Inselspital in Bern. The consequences are mainly depletion states that can result in the so-called "cancer fatigue syndrome".
The signature test of gene expression can give even more security in case of renunciation of the chemotherapy, and this in the long term. No other genetic testing is as good as EndoPredict in this area.
The right quantity and combination are essential: a blend of minerals, trace elements, vitamins and secondary plant substances can be an effective weapon in the fight against breast cancer. The teacher. Dr. Gerd Nagel, oncologist and president of the Patientenkompetenz Foundation, explains why it is important to help one another.
In recent years, gene expression analyzes are available: they can provide information on the behavior of each breast cancer. They thus offer greater security in the patient's personalized treatment decision. Two experts from the cantonal hospital in Lucerne tell us about the possibilities and limits of these tests. Dr. med. Stefan Aebi, Chief Medical Officer of Oncology and Prof. Dr. Dr. med. Joachim Diebold, Chief Medical Officer of the Department of Pathology.
We think very little about breast cancer: in the metastatic stage, breast cancer is almost never curable. This situation affects a large number of women, of whom there is very little talk: women over 50.
A recent survey showed that most people do not know that advanced breast cancer is almost always fatal. The European campaign "Here & Now" of the pharmaceutical group Novartis aims to improve the information on this fact and thus to support the women concerned.
Due to a hereditary genetic defect, Birgit Steiner * has had breast cancer. We talked about her experience and her treatment with her and with Dr. Dr. Knauer, the surgeon of breast surgery at the Cantonal Hospital of St. Gallen.
She is a prime example of the "happy" outcome of breast cancer. "Happy" because Julia Jansen's cancer was detected at an early stage. "Happy" also because this retiree was so little intimidated by his illness: we explain it to you in a conversation with Julia Jansen and her doctor the Prof. Dr. Knauer, Chief Medical Officer of Breast Surgery at the Cantonal Hospital of St. Gallen.
From the initial diagnosis, Rosemarie Graf * 's breast cancer had already spread to the axillary ganglia. She followed chemotherapy, then the operation and finally other treatments. Years later, this woman approaching her sixties struggled a second time against breast cancer.
In most cases, it is in the tumor bed that the success or failure of a breast cancer operation is decided. After the excision of the tumor, the risk of restarting the tumor is greatest in the transition zone between the affected tissues and the healthy tissues. It is for this reason that radiotherapy exactly targets this area of ??the breast. Most of the time, however, conventional radiotherapy takes place several weeks after the procedure itself: the tumor bed is often not precisely achieved. With INTRABEAM, Carl Zeiss's new irradiation device, irradiation is possible directly after the operation. Early studies have shown that the risk of relapse is extremely low.
"Cytostatics inhibit the metabolic cycles responsible for growth or cell division. Their goal is to destroy rapidly growing cancer cells as quickly as possible, but they reach other healthy cells with rapid division, such as skin cells or mucous membranes, "explains Professor Robert Hunger, dermatologist at Of the Inselspital of Bern.
After chemotherapy, patients with breast cancer may suffer for a long time from apathy and fatigue. The good news is that it is possible to do something against this cancer-related fatigue, also called Cancer Related Fatigue (CRF). Dr. Morant, FMH specialist in oncology-hematology and medical director of Tumorzentrum ZeTuP St. Gallen, Rapperswil and Chur, describes the context and treatment possibilities.
A new genetic test that uses the "Next Generation Sequencing (NGS)" method now analyzes a large number of genes. On the occasion of the introduction of the "myRisk" test in Zurich, international experts discussed at the symposium of the manufacturer Myriad Genetics the chances and challenges of multi-panel genetic testing. MyRisk analyzes at the same time 25 genes that considerably influence the risk of eight common types of cancer: breast, intestine, ovarian, uterine, stomach, pancreatic, skin and prostate.
Active substances and treatments are always more ingenious against advanced HER-2 positive breast cancer. We discussed with Prof. Dr. med. Beat ThÃ¼rlimann, Chief Medical Officer and Director of the Breast Center of the St. Gallen Cantonal Hospital, the latest treatment recommendations and the hopes of research for years to come.
Patients and their families can derive considerable benefit from an innovative test for predisposition to hereditary cancers. Indeed, "myRisk" analyzes not only one gene but 25 genes linked to eight types of hereditary cancers: this saves time and knowledge in defining the appropriate treatment.